Natasha Bahri, MD

Assistant Professor

Publications
  1. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. Journal of hematology & oncology. 2021. PMID: 34404440


  2. Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PloS one. 2020. PMID: 32866200


  3. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood advances. 2020. PMID: 32706892


  4. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood advances. 2020. PMID: 32433744


  5. Tsuang A, Menon NR, Bahri N, Geyman LS, Nowak-Wegrzyn A. Risk factors for multiple epinephrine doses in food-triggered anaphylaxis in children. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2018. PMID: 29940309